LANGHORNE, Pa., June 25, 2015 (GLOBE NEWSWIRE) -- Alliqua BioMedical, Inc. (Nasdaq:ALQA) ("Alliqua" or "the Company"), a provider of advanced wound care products today announced that a review of an observational study, focusing on the use of the Company's Biovance Amniotic Tissue Allograft to treat chronic wounds was published in WOUNDS, the most widely-read, peer-reviewed journal focusing on wound care and wound research.
The review, authored by Janice Smiell, Terry Treadwell, Helen Hahn and Michel Hermans, is titled, Real-world Experience with a Decellularized, Dehydrated Human Amniotic Membrane Allograft1. It is focused on the chronic wound data subset from a larger observational study with 230 subjects/244 chronic and acute wounds at 19 centers across the US. This review includes 165 subjects with 179 chronic wounds across the 15 wound care centers that treated chronic wounds.
"This review demonstrates what can be expected when treating chronic wounds in patients with multiple comorbidities in the real-world-setting, without the restrictions of inclusion and exclusion criteria found in prospective randomized controlled trials," said Dr. Janice Smiell, Alliqua's Chief Medical Officer. "It was an 'all comers' study; only patients with actively infected wounds or known hypersensitivity to decellularized, dehydrated human amniotic membrane allografts were excluded. More than half of the 165 subjects included in our sample would have been excluded from a randomized, controlled trial because of comorbid conditions."
"Despite the presence of factors and comorbidities, which may have a negative impact on healing, 49.6% of compliant patients with chronic wounds achieved complete wound closure at a mean-time-to closure of 7.4 weeks (median 6.3 weeks), including many cases where prior treatment with advanced biological therapies had failed. This is an improvement over the wound closure outcomes in the standard care control arms of prospective randomized studies with venous or diabetic ulcers are reported to be between 24 and 34%. As my co-authors and I concluded, these findings demonstrate the effectiveness of human amniotic membrane allografts like Biovance in a broad, real-world population of all types of chronic wounds. In the health care environment of 2015, where health care providers are increasingly reliant on quality metrics and real-world data, we believe that this study will help practitioners to more effectively navigate the challenges brought by the complexities of chronic wounds."
Click to expand...